Atara Biotherapeutics, Inc.

Listed Company

ATRACIK 0001604464NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$32.69M

Total Assets

$20.23M

Equity

$-38.50M

Shares Out

9.01M

Op. Cash Flow

$-50.94M

ATRA$8.48−13.08% · past yearDBEQ Basic

Daily closing prices

Business

Atara Biotherapeutics is a biopharmaceutical company developing T-cell immunotherapies using its proprietary allogeneic EBV T-cell platform. Its lead product, tab-cel (Ebvallo), an allogeneic EBV-specific T-cell therapy, has received regulatory approval in Europe and the UK for EBV+ post-transplant lymphoproliferative disease and is in Phase 3 development in the U.S.; the company has paused development of CAR T programs (ATA3219 and ATA3431) and transferred substantial manufacturing, clinical, development, and regulatory responsibilities to commercial partner Pierre Fabre. The company operates through an exclusive worldwide commercialization partnership with Pierre Fabre under an amended and restated agreement.

Summary from 10-K filed 2026-03-16

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Commercialization revenue	121	129	8	0	—
Total revenue	121	129	9	64	—
Cost of commercialization revenue	21	21	9	0	—
Research and development expenses	37	151	225	273	282
General and administrative expenses	26	40	51	72	79
Total costs and operating expenses	85	212	285	344	—
Loss from operations	36	−83	−276	−281	−340
Interest income	683,000	2	5	3	—
Interest expense	−4	−5	−5	−373,000	—
Other income (expense), net:	−34,000	528,000	−246,000	−700,000	367,000
Total other income (expense), net	−3	−2	−105,000	52	367,000
Loss before provision for (benefit from) income taxes	33	−85	−276	−228	−340
Provision for (benefit from) income taxes	31,000	−12,000	15,000	12,000	46,000
Net loss	33	−85	−276	−228	−340
Unrealized gain (loss) on available-for-sale securities	−7,000	212,000	2	−2	−664,000
Comprehensive loss	33	−85	−274	−230	−341
Basis net loss per common share	2.61	−11.41	−65.19	−2.24	−3.63
Diluted net loss per common share	2.57	−11.41	−65.19	−2.24	−3.63
Basic weighted-average shares outstanding	13	7	4	102	94
Diluted weighted-average shares outstanding	13	7	4	102	94

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	8	25	26	93	106
Short-term investments	0	17	26	150	265
Restricted cash	0	146,000	146,000	146,000	194,000
Accounts receivable	1	1	34	40	986,000
Inventories	0	11	10	2	0
Other current assets	2	10	6	10	12
Total current assets	12	65	102	295	385
Property and equipment, net	73,000	1	4	6	54
Operating lease assets	7	40	55	68	26
Other assets	886,000	3	5	7	2
Total assets	20	109	166	376	468
Accounts payable	127,000	4	4	7	17
Accrued compensation	1	7	12	18	25
Accrued research and development expenses	82,000	8	17	25	13
Deferred revenue	716,000	95	78	8	41
Liability related to the sale of future revenues - current portion	10	382,000	—	—	—
Other current liabilities	3	20	32	21	9
Total current liabilities	15	135	142	79	106
Operating lease liabilities - long-term	9	30	46	58	26
Liability related to the sale of future revenues - long-term	33	39	35	30	0
Other long-term liabilities	2	3	5	6	2
Total liabilities	59	206	265	250	189
Commitments and contingencies (Note 9)	—	—	—	—	—
Common stock - $0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024, respectively; 7,324 and 5,859 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1,000	1,000	0	10,000	9,000
Additional paid-in capital	1,983	1,957	1,870	1,822	1,745
Accumulated other comprehensive income	1,000	8,000	−204,000	−2	−368,000
Accumulated deficit	−2,022	−2,055	−1,969	−1,693	−1,465
Total stockholders' equity (deficit)	−39	−97	99	127	280
Total liabilities and stockholders' equity (deficit)	20	109	166	376	468

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	33	−85	−276	−228	−340
Stock-based compensation expense	10	27	45	54	54
Non-cash operating lease expense	5	12	12	9	2
Depreciation and amortization expense	2	5	5	6	9
Accretion of liability related to sale of future revenues	4	4	5	0	87,000
Amortization (accretion) of investment premiums (discounts)	259,000	−240,000	792,000	1	2
Loss on impairment of lease right-of-use asset	4	0	—	—	—
Gain on derecognition of lease liabilities upon contract assignment	−4	0	—	—	—
Other non-cash items, net	94,000	−402,000	214,000	147,000	108,000
Accounts receivable	229,000	33	6	−39	264,000
Inventories	11	−4	−8	−2	0
Other current assets	6	−1	273,000	2	—
Other assets	15,000	19,000	—	—	−2
Accounts payable	−4	687,000	−3	−9	9
Accrued compensation	−5	−5	−6	−7	5
Accrued research and development expenses	−8	−9	−4	12	−2
Other current liabilities	−5	−13	11	2	2
Deferred revenue	−94	−20	30	−11	35
Operating lease liabilities	−5	−11	−13	−8	−2
Other long-term liabilities	1,000	−462,000	142,000	354,000	−509,000
Net cash used in operating activities	−51	−69	−193	−270	−221
Purchases of short-term investments	−8	−20	−84	−181	−301
Proceeds from maturities and sales of short-term investments	25	29	209	293	334
Purchases of property and equipment	0	−246,000	−1	−4	−11
Proceeds from sale of property and equipment	948,000	0	25,000	0	0
Net cash provided by investing activities	18	9	124	203	22
Proceeds from sale of common stock and pre-funded warrants in registered direct offerings, net	15	51	—	—	—
Proceeds from issuance of common stock through ATM facilities, net	1	9	2	22	99
Proceeds from employee stock awards	35,000	230,000	928,000	2	7
Principal payments on finance lease obligations	−250,000	−892,000	−947,000	−518,000	−254,000
Other financing activities, net	−1,000	−7,000	−13,000	−192,000	−17,000
Net cash provided by financing activities	16	59	2	53	104
Decrease in cash, cash equivalents and restricted cash	−17	−811,000	−67	−14	−94
Cash paid for interest	286,000	685,000	447,000	335,000	32,000
Cash paid for income taxes	190,000	24,000	2,000	19,000	15,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Atara Biotherapeutics, Inc.'s CIK number?

Atara Biotherapeutics, Inc.'s SEC CIK number is 0001604464 (1604464). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Atara Biotherapeutics, Inc.'s SEC filings?

All of Atara Biotherapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Atara Biotherapeutics, Inc. last report earnings?

Atara Biotherapeutics, Inc. (ATRA) most recently filed an earnings 8-K with the SEC on Mar 16, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-108344). This is Atara Biotherapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Atara Biotherapeutics, Inc.'s most recent earnings 8-K?

Atara Biotherapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 16, 2026 under accession 0001193125-26-108344. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Atara Biotherapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →